# Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST)

> **NCT03648554** · PHASE4 · UNKNOWN · sponsor: **Central Hospital, Nancy, France** · enrollment: 93 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2
- NASH - Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** dulaglutide (TRULICITY®) 1.5 mg
- **OTHER:** reinforced dietary monitoring

## Key facts

- **NCT ID:** NCT03648554
- **Lead sponsor:** Central Hospital, Nancy, France
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-01
- **Primary completion:** 2023-09-30
- **Final completion:** 2024-03-30
- **Target enrollment:** 93 (ESTIMATED)
- **Last updated:** 2019-06-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03648554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03648554, "Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03648554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*